Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen.

| 2016 News Releases, Corporate News, Featured | No Comments
Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen.  This program helps…

FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

| 2015 News Releases, Corporate News, Thyroid Cancer | No Comments
Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…

U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients

| 2014 News Releases, Corporate News, Featured, Hypothyroidism, Radioactive Iodine, Thyroid Cancer | No Comments
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid…

Return of LEVOXYL® to market

| Corporate News, Goiter, Hypothyroidism | No Comments
February 2014 - Pfizer is pleased to announce that LEVOXYL® (levothyroxine sodium), a prescription medicine…

Phase 3 Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival in Radioiodine-Refractory Differentiated Thyroid Cancer

| Corporate News | No Comments
Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3…

FDA approves sorafenib for thyroid carcinoma

| Corporate News, Thyroid Cancer | No Comments
From the American Thyroid Association: In collaboration with the Food and Drug Administration (FDA), and…

AstraZeneca News

| Corporate News | No Comments
AstraZeneca is pleased to announce two new clinical trials for patients with differentiated thyroid cancer.…

Nexavar Thyroid Priority Review Designation

| Corporate News | No Comments
Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug…

ATA Announces Launch of Corporate Information & Opportunities Webpage and Information Submission Portal

| Corporate News | No Comments
The ATA is pleased to confirm the launch of the ATA Corporate Information & Opportunities…